Plus   Neg

Stock Alert: Humanigen Climbs 30% After Positive News On Its Lenzilumab

Shares of clinical-stage biopharmaceutical company, Humanigen, Inc. (HGEN) jumped more than 30% Tuesday morning and touched a new high of $6.79.

Monday, Humanigen said that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) has selected Lenzilumab, the company's late-stage drug candidate in Covid-19 for Big Effect Trial (BET) in SARS-CoV-2 infected patients.

Lenzilumab will be evaluated in combination with Gilead Sciences' remdesivir and compared to placebo and remdesivir.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT